Is early virological response as predictive of the hepatitis C treatment response in dialysis patients as in non-uremic patients?

International Journal of Infectious Diseases

Volumn 17, Issue 1, 2013, Pages

  Fucuta Pereira, Patricia da Silva ^a   Uehara, Silvia Naomi de Oliveira ^a   de Mello Perez, Renata ^a   Feldner, Ana Cristina Amaral ^a   de Melo, Isaura Cunha ^a   de Souza e Silva, Ivonete Sandra ^a   Silva, Antonio Eduardo Benedito ^a   Ferraz, Maria Lucia Gomes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dialysis; HCV RNA; Hepatitis C; Interferon; Predictive value

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEMOGLOBIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DIABETES MELLITUS; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; MONOTHERAPY; PERITONEAL DIALYSIS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BRAZIL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872271888     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.09.001     Document Type: Article

References (45)

1. Jadoul M., Cornu C., van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998, 53:1022-1025.
2. Jadoul M., Poignet J.L., Geddes C., Locatelli F., Medin C., Krajewska M., et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004, 19:904-909.
3. Finelli L., Miller J.T., Tokars J.I., Alter M.J., Arduino M.J. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005, 18:52-61.
4. Huraib S., al-Rashed R., Aldrees A., Aljefry M., Arif M., al-Faleh F.A. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies. Nephrol Dial Transplant 1995, 10:470-474.
5. Sesso R.C., Lopes A.A., Thome F.S., Lugon J.R., Santos D.R. 2010 report of the Brazilian Dialysis Census. J Bras Nefrol 2011, 33:442-447.
6. Sociedade Brasileira de Nefrologia. Censo Brasileiro de diálise. Brazilian Society of Nephrology; 1999. Available at: (accessed August 2012). http://www.nefrologiaonline.com.br/Censo/censo99.asp.
7. Nakayama E., Akiba T., Marumo F., Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000, 11:1896-1902.
8. Kalantar-Zadeh K., McAllister C.J., Miller L.G. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant 2005, 20:1662-1669.
9. Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999, 354:93-99.
10. Cruzado J.M., Carrera M., Torras J., Grinyo J.M., Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001, 1:171-178.
11. Mahmoud I.M., Elhabashi A.F., Elsawy E., El-Husseini A.A., Sheha G.E., Sobh M.A. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis 2004, 43:131-139.
12. Mathurin P., Mouquet C., Poynard T., Sylla C., Benalia H., Fretz C., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999, 29:257-263.
13. Hanafusa T., Ichikawa Y., Kishikawa H., Kyo M., Fukunishi T., Kokado Y., et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998, 66:471-476.
14. Zylberberg H., Nalpas B., Carnot F., Skhiri H., Fontaine H., Legendre C., et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002, 17:129-133.
15. Rostaing L., Modesto A., Baron E., Cisterne J.M., Chabannier M.H., Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron Clin Pract 1996, 74:512-516.
16. Tokumoto T., Tanabe K., Ishikawa N., Simizu T., Oshima T., Noguchi S., et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplant Proc 1998, 30:3270-3272.
17. Hanafusa T., Ichikawa Y., Yazawa K., Kishikawa H., Fukunishi T., Kanai T., et al. Hepatitis C virus infection in kidney transplantation and a pilot study of the effects of interferon-alpha therapy. Transplant Proc 1998, 30:122-124.
18. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
19. Fabrizi F., Dixit V., Messa P., Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008, 15:79-88.
20. Rocha C.M., Perez R.M., Ferreira A.P., Carvalho-Filho R.J., Pace F.H., Silva I.S., et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006, 26:305-310.
21. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645-652.
22. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
23. Perez R.M., Ferraz M.L., Figueiredo M.S., Contado D., Koide S., Ferreira A.P., et al. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003, 69:489-494.
24. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
25. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997;26(Suppl 1):2S-10S.
26. Degos F., Pol S., Chaix M.L., Laffitte V., Buffet C., Bernard P.H., et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001, 16:1017-1023.
27. Uchihara M., Izumi N., Sakai Y., Yauchi T., Miyake S., Sakai T., et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron Clin Pract 1998, 80:51-56.
28. Rostaing L., Chatelut E., Payen J.L., Izopet J., Thalamas C., Ton-That H., et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998, 9:2344-2348.
29. Russo M.W., Goldsweig C.D., Jacobson I.M., Brown R.S. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003, 98:1610-1615.
30. Fabrizi F., Dulai G., Dixit V., Bunnapradist S., Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003, 18:1071-1081.
31. Gordon C.E., Uhlig K., Lau J., Schmid C.H., Levey A.S., Wong J.B. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008, 51:263-277.
32. Alavian S.M., Tabatabaei S.V. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis 2010, 4:181-194.
33. Fabrizi F., Dixit V., Messa P., Martin P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Med Virol 2010, 82:768-775.
34. Heathcote E.J. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007, 14(Suppl 1):82-88.
35. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
36. Muir A.J., Bornstein J.D., Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
37. Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E., Afdhal N., et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
38. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., Salmeron J., Diago M., Fernandez-Rodriguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-641.
39. Poustchi H., Negro F., Hui J., Cua I.H., Brandt L.R., Kench J.G., et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008, 48:28-34.
40. Reddy K.R., Shiffman M.L., Morgan T.R., Zeuzem S., Hadziyannis S., Hamzeh F.M., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124-129.
41. Dusheiko G., Nelson D., Reddy K.R. Ribavirin considerations in treatment optimization. Antivir Ther 2008, 13(Suppl 1):23-30.
42. Liu C.H., Liang C.C., Lin J.W., Chen S.I., Tsai H.B., Chang C.S., et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008, 57:525-530.
43. Hanrotel C., Toupance O., Lavaud S., Thiefin G., Brodard V., Ingrand D., et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron Clin Pract 2001, 88:120-126.
44. Gordon C.E., Uhlig K., Lau J., Schmid C.H., Levey A.S., Wong J.B. Interferon for hepatitis C virus in hemodialysis-an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol 2009, 4:1449-1458.
45. Kidney Disease Improving Global Outcomes KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008, 73:S1-S99.